BEAM vs FDMT
BEAM: Beam Therapeutics is a biotechnology firm pioneering base editing technology to create next-generation precision genetic medicines. FDMT: 4D Molecular Therapeutics is a clinical-stage biotechnology company pioneering targeted genetic medicines to transform the treatment of debilitating ophthalmological and pulmonary diseases.
Side-by-side fundamentals
| Metric | BEAM | FDMT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $24.60 | $12.70 | |
| Market cap | $2.5B | $632M | |
| Net margin FY2025, SEC XBRL | -57.2% | -164.4% | BEAM higher |
| Operating margin FY2025, SEC XBRL | -274.6% | -187.2% | FDMT higher |
| ROE FY2025, SEC XBRL | -6.5% | -27.7% | BEAM higher |
| ROA FY2025, SEC XBRL | -5.4% | -24.7% | BEAM higher |
| Debt / equity as of 2026-09-03 | 0.09 | 0.00 | FDMT lower |
| Revenue CAGR (3y) SEC XBRL | +31.9% | +200.9% | FDMT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.80 | 1.18 | |
| 1-year return as of 2026-10-08 close | -8.9% | +31.5% | FDMT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.